To the editor: As the specialist laboratory providing chikungunya virus (CHIKV) diagnostics to the National Health Service (NHS) across the United Kingdom (UK), we read with interest the rapid communication by Javelle et al. [1] regarding the chikungunya outbreak in Thailand at the beginning of 2019.

Alongside the two UK cases reported in the paper, we diagnosed a further two CHIKV infections in travellers returning to the UK from Thailand in the same timeframe (the molecular assay used is based on the method of Edwards et al. [2], rather than Pastorino et al. [3], as was incorrectly indicated in the published paper). Case 1 recovered completely within 3 weeks, but case 2, an older individual, has been referred to rheumatology for management of persistent arthralgia, which has improved after a course of steroids (Table).

The two additional cases we diagnosed were not reported to any of the data collection networks for the surveillance of travel-related illness. This indicates a limitation of surveillance networks that receive their data from the medical centres where patients are clinically assessed, rather than the laboratories that diagnose the infections. With this in mind, it is likely that there were more chikungunya infections from Thailand diagnosed in specialist laboratories across Europe in the first two months of 2019 than were reported to EuroTravNet/GeoSentinel or TropNet.

Currently, national public health bodies across the European Union/ European Economic Area (EU/EEA) report laboratory diagnoses of CHIKV infection to the European Centre for Disease Prevention and Control on an annual basis via the European Surveillance System (TESSy) [4]. Timely information on the numbers and sources of imported infections is therefore not available. We wonder whether a laboratory-based system of monthly or semi-monthly notifications of imported infections such as dengue and chikungunya could be considered.

TESSy is a system for the collection, analysis and dissemination of data on communicable diseases. Indeed, there is precedent for TESSy to be used for more regular reporting of data; at the time of the Zika virus (ZIKV) outbreak in 2016, ZIKV diagnoses data from across the EU/EEA were collected weekly for real-time surveillance. Direct laboratory notifications might contribute less clinical data than clinician notifications of laboratory-diagnosed imported infections such as chikungunya and dengue; nevertheless, we suggest that the routine availability of timely information regarding the countries of origin of CHIKV and dengue virus infections imported into Europe would be invaluable to providers of both pre-travel advice and healthcare for returning travellers.
Conflict of interest

None declared.

Authors’ contributions

Conception: EA. Wrote first draft: KM. Reviewed, edited and approved the final version: KM, GB-M, DB and EA.

References


License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2019.

### Table

Overview of two further confirmed chikungunya cases among travellers returning from Thailand to the UK, January–February 2019 (n = 2)

<table>
<thead>
<tr>
<th>Case</th>
<th>Reporting Country</th>
<th>Place visited</th>
<th>Period of exposure</th>
<th>Age (years)</th>
<th>Underlying conditions</th>
<th>Date of onset</th>
<th>Clinical acute symptoms</th>
<th>Outcome</th>
<th>Recovery status as at 9 May 2019</th>
<th>Diagnosis method (positive tests)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>UK</td>
<td>Unknown</td>
<td>December 2018–January 2019</td>
<td>40</td>
<td>None</td>
<td>January 2019</td>
<td>Rash, fever, headache, arthralgia, myalgia</td>
<td>Recovered</td>
<td>Yes</td>
<td>CHIKV RT-PCR [2] and anti-CHIKV IgM ELISA (Euroimmun, Lubeck, Germany) on day 5</td>
</tr>
<tr>
<td>2</td>
<td>UK</td>
<td>Koh Lanta</td>
<td>Unknown–February 2019</td>
<td>60</td>
<td>None</td>
<td>Unknown</td>
<td>Fever, headache and synovitis of small and large joints</td>
<td>Persistent arthralgia</td>
<td>No</td>
<td>CHIKV RT-PCR [2]</td>
</tr>
</tbody>
</table>

UK: United Kingdom.

* Rounded to the nearest 5-year group.